Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02445807 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis
A Phase 3 study, sponsored by Promius Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 265
- Enrollment target
NCT02445807: Completed Phase 3 study, sponsored by Promius Pharma.
NCT02445807 is a Phase 3 study that has completed, run by Promius Pharma. The registered enrollment target is 265 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02445807, a Phase 3 study, has completed, sponsored by Promius Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 265 participants
- Enrollment target
Study Summary
This study will compare the efficacy and safety of DFD-06 Cream to Vehicle Cream for topical treatment of moderate to severe plaque psoriasis after 3, 7, and 14 days of treatment.
Primary Outcome
The primary efficacy endpoint is the percentage of subjects with treatment success (defined as IGA = 0 or 1 and at least a 2 grade reduction from Baseline) at the Day 15 visit. The primary analysis was done with multiple imputations. Results are combined analyses from 5 imputed data sets.
Interventions
- DRUG Vehicle Cream
- DRUG DFD06-Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-07 |
| Phase | Phase 3 |
What the finished NCT02445807 record still lists
NCT02445807 is an interventional study that assigns participants to a tested intervention. The registered 265 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle Cream is the first listed.
NCT02445807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02445807 about?
NCT02445807 is a clinical study titled "A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis". This study will compare the efficacy and safety of DFD-06 Cream to Vehicle Cream for topical treatment of moderate to severe plaque psoriasis after 3, 7, and 14 days of treatment.
What is the current status of trial NCT02445807?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 265 participants. The study started on 2015-12. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02445807?
The interventions under investigation include: Vehicle Cream (DRUG), DFD06-Cream (DRUG).
Who is sponsoring clinical trial NCT02445807?
This trial is sponsored by Promius Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02445807's enrollment target sits among peer trials
265 1223rd of 2000 higher than 776 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443126 · 265 participants · Phase 1
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
- NCT05470491 · 265 participants · Phase 1
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- NCT07301905 · 265 participants · NA
Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI
- NCT07470853 · 265 participants · Phase 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia